High-Quality Manufacturing CorePharma operates four state-of-the-art FDA- and DEA-registered facilities with a total capacity supporting up to 5 billion dosage units annually. This positions them as a reliable partner for large-scale pharmaceutical manufacturing and contract development needs, especially for companies seeking high-volume production capabilities.

Comprehensive Services Offering end-to-end solutions from early-stage drug development through commercial launch, CorePharma provides integrated support across all stages of the pharmaceutical lifecycle, making it ideal for clients looking for a single partner to streamline their development and manufacturing processes.

Leadership Stability Recent leadership appointments, including the hiring of President and Chairman Vithal Dhaduk and CEO Arpit Patel, indicate a stable and strategically guided company focused on growth and operational excellence, which can appeal to clients seeking a secure partnership in a competitive market.

Financial Consistency With an annual revenue estimated between $100 million and $250 million, CorePharma demonstrates solid financial stability, enabling sufficient investment in technology, capacity, and quality enhancements that can support clients' long-term manufacturing demands.

Market Focus and Scale Operating within the U.S. pharmaceutical manufacturing sector with a sizable technical infrastructure and focused therapeutic support, CorePharma is well-positioned to serve mid-sized to large pharma companies looking for a reliable CDMO partner with proven regulatory expertise and rapid lead times.